Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil

Reuters03-28

Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil

Biodexa published audited preliminary results for the year ended Dec. 31, 2025.
The company reported no revenue and a loss attributable to owners of the parent of GBP 6.38 million.
R&D expenditure fell 27.2% to GBP 3.96 million, reflecting lower spend on preclinical and manufacturing work for tolimidone, reduced MTX110 spending, and lower eRapa costs net of CPRIT grant income.
Administrative costs rose 27% to GBP 4.84 million, driven by GBP 0.44 million of foreign exchange movement and GBP 0.73 million higher professional fees.
Stephen Stamp said 2026 priorities include accelerating enrollment in the Phase 3 Serenta trial of eRapa in FAP and manufacturing clinical supplies to initiate a Phase 1b/2a study of MTX240 in GIST.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271700PRIMZONEFULLFEED1001172730) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622803903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622803903","market":"us","top_or_hot":-1,"title":"Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Biodexa published audited preliminary results for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          The company reported no revenue and a loss attributable to owners of the parent of GBP 6.38 million.\n        </li>\n<li>\n          R&amp;D expenditure fell 27.2% to GBP 3.96 million, reflecting lower spend on preclinical and manufacturing work for tolimidone, reduced MTX110 spending, and lower eRapa costs net of CPRIT grant income.\n        </li>\n<li>\n          Administrative costs rose 27% to GBP 4.84 million, driven by GBP 0.44 million of foreign exchange movement and GBP 0.73 million higher professional fees.\n        </li>\n<li>\n          Stephen Stamp said 2026 priorities include accelerating enrollment in the Phase 3 Serenta trial of eRapa in FAP and manufacturing clinical supplies to initiate a Phase 1b/2a study of MTX240 in GIST.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271700PRIMZONEFULLFEED1001172730) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Biodexa published audited preliminary results for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          The company reported no revenue and a loss attributable to owners of the parent of GBP 6.38 million.\n        </li>\n<li>\n          R&amp;D expenditure fell 27.2% to GBP 3.96 million, reflecting lower spend on preclinical and manufacturing work for tolimidone, reduced MTX110 spending, and lower eRapa costs net of CPRIT grant income.\n        </li>\n<li>\n          Administrative costs rose 27% to GBP 4.84 million, driven by GBP 0.44 million of foreign exchange movement and GBP 0.73 million higher professional fees.\n        </li>\n<li>\n          Stephen Stamp said 2026 priorities include accelerating enrollment in the Phase 3 Serenta trial of eRapa in FAP and manufacturing clinical supplies to initiate a Phase 1b/2a study of MTX240 in GIST.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271700PRIMZONEFULLFEED1001172730) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLshgDc:1","article_id":"2622803903","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622803903","pubTimestamp":1774645249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biodexa published audited preliminary results for the year ended Dec. 31, 2025.The company reported no revenue and a loss attributable to owners of the parent of GBP 6.38 million.R&D expenditure fell 27.2% to GBP 3.96 million, reflecting lower spend on preclinical and manufacturing work for tolimidone, reduced MTX110 spending, and lower eRapa costs net of CPRIT grant income.Administrative costs rose 27% to GBP 4.84 million, driven by GBP 0.44 million of foreign exchange movement and GBP 0.73 million higher professional fees.Stephen Stamp said 2026 priorities include accelerating enrollment in the Phase 3 Serenta trial of eRapa in FAP and manufacturing clinical supplies to initiate a Phase 1b/2a study of MTX240 in GIST.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BDRX":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4139":"生物科技"},"translate_title":"Biodexa Pharmaceuticals 2025财年运营亏损收窄6.02%至860万英镑；收入为零","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BDRX":0.9},"content_text":"Biodexa Pharmaceuticals FY2025 operating loss narrows 6.02% to £8.6 million; revenue was nil\n    \n\n\n          Biodexa published audited preliminary results for the year ended Dec. 31, 2025.\n        \n\n          The company reported no revenue and a loss attributable to owners of the parent of GBP 6.38 million.\n        \n\n          R&D expenditure fell 27.2% to GBP 3.96 million, reflecting lower spend on preclinical and manufacturing work for tolimidone, reduced MTX110 spending, and lower eRapa costs net of CPRIT grant income.\n        \n\n          Administrative costs rose 27% to GBP 4.84 million, driven by GBP 0.44 million of foreign exchange movement and GBP 0.73 million higher professional fees.\n        \n\n          Stephen Stamp said 2026 priorities include accelerating enrollment in the Phase 3 Serenta trial of eRapa in FAP and manufacturing clinical supplies to initiate a Phase 1b/2a study of MTX240 in GIST.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271700PRIMZONEFULLFEED1001172730) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622803903","isCrawlerRequest":true}